Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launc
Post# of 341
(Total Views: 213)
Posted On: 11/11/2021 3:38:57 PM
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Transformative Training Program for Psychedelic Facilitators
- The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced
- Program offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatment
- EMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework
In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing support and guidance in the space becomes even more important. With that in mind, Cybin (NEO: CYBN) (NYSE American: CYBN) has launched its proprietary EMBARK Psychedelic Facilitator Training Program (https://nnw.fm/qiHVU).
Named for the program’s six clinical domains — Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, Keeping Momentum — the EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced in psychedelic treatment, as well as the equally broad training therapists need to facilitate the treatment.
“Psychedelic medicines and the great healing potential they hold have only just begun to find their place in our culture and its array of therapeutic approaches,” explained Bill Brennan, a cocreator of the program. “EMBARK represents an important step forward in that process.
“We designed it to be uniquely responsive to the distinctive and disruptive ways that these medicines heal people, while also able to incorporate synergistic aspects of other evidence-based treatments,” Brennan continued. “Its flexible, six-domain structure allows us to open the aperture on our notions of healing and expand our ability to help patients reach a place of wellness. We offer EMBARK in a spirit of service and deep respect for psychedelic medicines and the many avenues of healing they open to us.”
Led by an expert team, the program offers psychedelic clinical trial facilitators the foundational training needed to provide skillful and ethical care to participants receiving psychedelic treatment. With an emphasis on experiential learning, the training will kick off with an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state. The training includes an experiential training component, in addition to the core training and practice sessions on the EMBARK model.
Cybin’s EMBARK Psychedelic Facilitator Training Program is designed to prepare facilitators to work within the program’s six domains. The program enhances each facilitator’s individual therapeutic training and expertise by offering a flexible curriculum that emphasizes trauma-informed, culturally competent, and ethically rigorous care.
“We’re excited to host this training,” said Dr. Alex Belser, EMBARK’s coauthor and Cybin chief clinical officer. “When we first created EMBARK, we canvassed 20 different psychedelic-assisted psychotherapies. We found that some therapies left out important aspects, like people’s spiritual experiences, somatic experiences or human relationships.
“Patients were telling us that these experiences were central to their healing, but many therapies seemed to be missing critical pieces,” Dr. Belser continued. “To address this challenge, we developed EMBARK, which provides an open architecture to support the varieties of psychedelic experience within a coherent therapeutic framework. This is a patient-centered approach for the whole person.”
Cybin is focused on progressing psychedelic therapeutics, making it an ideal advocate and sponsor of the EMBARK approach. A leading biotechnology company, Cybin is working to progress psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced
- Program offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatment
- EMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework
In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing support and guidance in the space becomes even more important. With that in mind, Cybin (NEO: CYBN) (NYSE American: CYBN) has launched its proprietary EMBARK Psychedelic Facilitator Training Program (https://nnw.fm/qiHVU).
Named for the program’s six clinical domains — Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, Keeping Momentum — the EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced in psychedelic treatment, as well as the equally broad training therapists need to facilitate the treatment.
“Psychedelic medicines and the great healing potential they hold have only just begun to find their place in our culture and its array of therapeutic approaches,” explained Bill Brennan, a cocreator of the program. “EMBARK represents an important step forward in that process.
“We designed it to be uniquely responsive to the distinctive and disruptive ways that these medicines heal people, while also able to incorporate synergistic aspects of other evidence-based treatments,” Brennan continued. “Its flexible, six-domain structure allows us to open the aperture on our notions of healing and expand our ability to help patients reach a place of wellness. We offer EMBARK in a spirit of service and deep respect for psychedelic medicines and the many avenues of healing they open to us.”
Led by an expert team, the program offers psychedelic clinical trial facilitators the foundational training needed to provide skillful and ethical care to participants receiving psychedelic treatment. With an emphasis on experiential learning, the training will kick off with an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state. The training includes an experiential training component, in addition to the core training and practice sessions on the EMBARK model.
Cybin’s EMBARK Psychedelic Facilitator Training Program is designed to prepare facilitators to work within the program’s six domains. The program enhances each facilitator’s individual therapeutic training and expertise by offering a flexible curriculum that emphasizes trauma-informed, culturally competent, and ethically rigorous care.
“We’re excited to host this training,” said Dr. Alex Belser, EMBARK’s coauthor and Cybin chief clinical officer. “When we first created EMBARK, we canvassed 20 different psychedelic-assisted psychotherapies. We found that some therapies left out important aspects, like people’s spiritual experiences, somatic experiences or human relationships.
“Patients were telling us that these experiences were central to their healing, but many therapies seemed to be missing critical pieces,” Dr. Belser continued. “To address this challenge, we developed EMBARK, which provides an open architecture to support the varieties of psychedelic experience within a coherent therapeutic framework. This is a patient-centered approach for the whole person.”
Cybin is focused on progressing psychedelic therapeutics, making it an ideal advocate and sponsor of the EMBARK approach. A leading biotechnology company, Cybin is working to progress psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)